Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 10
Submit an article Journal homepage
39
Views
5
CrossRef citations to date
0
Altmetric
Review

Pharmacological interventions for the correction of ion transport defect in cystic fibrosis

Frédéric Becq Université de Poitiers, Institut de Physiologie et Biologie Cellulaires (IPBC) CNRS UMR 6187, 40 Avenue du Recteur Pineau 86022, Poitiers, France. [email protected]
&
Yvette Mettey Faculté de Médecine et Pharmacie, Laboratoire de Chimie Organique, 34 rue du Jardin des Plantes, 86005, Poitiers, France
Pages 1465-1483 | Published online: 25 Feb 2005

Bibliography

  • PILEWSKI JM, FRIZZELL RA: Role of CFTR in airway disease. Physiol Rev (1999) 79:215–255.
  • BARRETT KE, DHARMSATHAPHORN K: Mechanisms of Chloride Secretion in a Colonic Epithelial Cell Line. Lebenthal E, Duffey M (Eds). Raven, New York (1990):59–66.
  • CANESSA CM, SCHILD L, BUELL G et al: Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature (1994) 367:463–467.
  • •First molecular identification of ENaC.
  • BOUCHER RC, STUTTS MJ, KNOWLES MR, CANTLEY L, GATZY JT: Na + transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. Clin. Invest. (1986) 78:1245–1252.
  • RIORDAN JR, ROMMENS JM, KEREM B et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 245:1066–1073.
  • ••One of the historical papers reporting the identification of CFTR gene and its product.
  • HANRAHAN JW, GENTZSCH M, RIORDAN JR: The cystic fibrosis transmembrane conductance regulator (ABCC7). In: ABC Proteins: From Bacteria to Man. Holland IB, Cole S, Kuchler K, Higgins CF (Eds). Academic Press (2003):589–618.
  • TABCHARANI JA, CHANG X-B, RIORDAN JR, HANRAHAN JVV: Phosphorylation-regulated Cl- channel in CHO cells stably expressing the cystic fibrosis gene. Nature (1991) 352:628–631.
  • •The first single-channel study on CFTR and its regulation.
  • LINTON KJ, ROSENBERG ME KERR ID, HIGGINS CF: Structure of ABC transporters. In: ABC Proteins: From Bacteria to Man. Holland TB, Cole S, Kuchler K, Higgins CF (Eds) Academic Press (2003):65–80.
  • SHEPPARD DN, WELSH MJ: Structureand function of the CFTR chloride channel. Physiol Rev (1999) 79:23–45.
  • SCHWIEBERT EM, BENOS DJ, EGAN ME, STUTTS J, GUGGINO WB: CFTR is a conductance regulator as well as a chloride channel. Physiol Rev (1999) 79:145–166.
  • GADSBY DC, NAIRN AC: Contol of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev (1999) 79:77–107.
  • BECQ F, JENSEN TJ, CHANG X-B et al: Phosphatase inhibitors activate normal and defective CFTR chloride channels. Proc. Natl. Arad .Sci. USA (1994) 91:9160–9164.
  • •This report showed the importance of phosphatases in the regulation of CFTR.
  • RATJEN F, DORING G: Cystic fibrosis. Lancet (2003) 361:681–689.
  • WELSH MJ, SMITH AE: Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 73:1251–1254.
  • •Classification of CFTR mutations.
  • CHENG SH, GREGORY RJ, MARSHALL J et al.: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell (1990) 63:827–834.
  • ••First evidence that delF508 is misfolded.
  • GELMAN MS, KOPITO RR: Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis. Clin. Invest. (2002) 110:1591–1597.
  • THOMAS PJ, SHENBAGAMURTHI P, SONDEK J, HULLIHEN JM, PEDERSEN PL: The cystic fibrosis transmembrane conductance regulator. Effects of the most common cystic fibrosis-causing mutation on the secondary structure and stability of a synthetic peptide. J. Biol. Chem. (1992) 267:5727–5730.
  • WARD CL, OMURA S, KOPITO RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell (1995) 83:122–127.
  • ••Molecular dissection of the degradationpathway of delF508.
  • CUTTING GR, KASCH LM, ROSENSTEIN BJ et al.: A cluster of cystic fibrosis mutations in the first nucleotide binding fold domain of the cystic fibrosis conductance regulator protein. Nature (1990) 346:366–369.
  • LOGAN J, HIESTAND D, DARAM P et al.: Cystic fibrosis transmembrane conductance regulator mutations that disrupt nucleotide binding. j. Clin. Invest. (1994) 94:228–326.
  • POWELL K, ZEITLIN PL: Therapeutic approaches to repair defects in AF508 CFTR folding and cellular targeting. Ad. Drug Del. Rev (2002) 54:1395–1408.
  • •Excellent up-to-date review of CF therapy.
  • DALEMANS W, BARBRY P, CHAMPIGNY G et al.: Altered chloride ion channel kinetics associated with the AF508 cystic fibrosis mutation. Nature (1991) 354:526–528.
  • ••First description of the Cr channel activityof delF508.
  • DRUMM ML, WILKINSON DJ, SMIT LS et al.: Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes. Science (1991) 254: 1797-1799.
  • MORELLO JP, PETAJA-REPO UE, BICHET DG, BOUVIER M: Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol ScL (2000) 21:466–469.
  • EIDELMAN 0, GUAY-BRODER C, VAN GALEN PJ et al.: Al adenosine-receptor antagonists activate chloride efflux from cystic fibrosis cells. Proc. Natl Acad. ScL USA (1992) 89:5562–5566.
  • •Identification of CPX as a delF508 agonist.
  • GUAY-BRODER C, JACOBSON KA, BARNOY ZI et al.: Al receptor antagonist 8-cyclopenty1-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator AF508 mutation. Biochemistry (1995) 34:9079–9087.
  • JACOBSON KA, GUAY-BRODER C, VAN GALEN PJ et al.: Stimulation by alkylxanthines of chloride efflux in CFPAC-1 cells does not involve Al adenosine receptors. Biochemistry (1995) 34:9088–9094.
  • ARISPE N, MA J, JACOBSON KA, POLLARD HB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopenty1-1,3-dipropylxanthine (CPX) and 1,3-dially1-8-cyclohexylxanthine (DAX)..I. Biol. Chem. (1997) 273:5727–5734.
  • COHEN BE, LEE G, JACOBSON KA et al.: 8-cyclopenty1-1-3-dipropylxanthine and other xanthines differentially bind to the wild-type and delta F508 first nucleotide binding fold (NBF-1) domains of the cystic fibrosis transmembrane conductance regulator. Biochemistry (1997) 36:6455–6461.
  • CHAPPE V, METTEY Y, VIERFOND J-M et al.: Structural basis for specificity and potency of xanthine derivatives as activators of the CFTR chloride channel. Br. J. Pharmacol (1998) 123:683–693.
  • •First SAR on CFTR activators.
  • McCARTY N, STANDART TA, TERESI M et al.: A Phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Ped. Palm. (2002) 33:90–98.
  • DENNING GM, ANDERSON MP, AMARA JF et al: Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature (1992) 358:761–764.
  • ••Demonstration that culturing CF cells atreduced temperature corrects abnormal location and function of delF508.
  • EDINGTON BV, WHELAN SA, HIGHTOWER LE: Inhibition of heat shock (stess) protein induction by deuterium oxide and glycerol: additional support for the abnormal protein hypothesis of induction.j Cell Physiol (1989) 139:219–228.
  • BROWN CR, HONG-BROWN LQ, BIWERSI J, VERKMAN AS, WELCH WJ: Chemical chaperones correct the mutant phenotype of the AF508 cystic fibrosis transmembrane conductance regulator protein. Cell Stess Chap. (1996) 1:117–125.
  • HOWARD M, FISCHER H, ROUX J et al.: Mammalian osmolytes and ..Cnitrosoglutathione promote AF508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function.j Biol. Chem (2003) 278:35159–35167.
  • ZHANG XM, WANG XT, YUE H et al: Organic solutes rescue the functional defect in AF508 cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. (2003) 278:51232–51242.
  • HAWORTH JC, DILLING LA, SURTEES RA et al.: Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am. I Med. Genet. (1993) 45:572–576.
  • CHENG SH, FANG SL, ZABNERJ et al:Functional activation of the cystic fibrosis trafficking mutant AF508-CFTR by overexpression. Am. Physiol (1995) 268:615–624.
  • RUBENSTEIN RC, EGAN ME, ZEITLIN PL: In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing AF508-CFTR. I Gin. Invest. (1997) 100:2457–2465.
  • •First description of the effect of 4-PBA in CF cells.
  • RUBENSTEIN RC, ZEITLIN PL: Sodium4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of AF508-CFTR. Am. I Phyiol. (2000) 278:259–267.
  • RUBENSTEIN RC, ZEITLIN PA: A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in AF508-homozygous cystic fibrosis patients. Am. I Respic Crit. Care Med. (1998) 157:484–490.
  • ZEITLIN PA, DIENER-WEST M, RUBENSTEIN RC et al.: Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Ther. (2002) 6:119–126.
  • BED WELL DM, KAENJAK A, BENOS DJ et al.: Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. (1997) 3:1280–1284.
  • WILCHANSKI M, YAHAV Y, YAACOV Y et al.: Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl. Med. (2003) 349:1433–1441.
  • EGAN ME, GLOCKNER-PAGEL J, AMBROSE CA et al: Calcium-pump inhibitors induce functional surface expression of AF508-CFTR protein in cystic fibrosis epithelial cells. Nat. Med. (2002) 8:485–492.
  • •First description of the correction by thapsigargin in CF cells.
  • EGAN ME, PEARSON M, WEINER SA et al.: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science (2004) 304:600–602.
  • LYTTON J, WESTLIN M, HANLEY MR: Thapsigargin inhibits the sarcoplasmic or endoplasmi reticulum Ca-ATPase family of calcium pumps. ". Biol. Chem. (1991) 266:17067–17071.
  • BECQ F, METTEY Y, GRAY MA et al.: Development of substituted benzo[c]quinolizinium compounds as novel activators of the cystic cibrosis chloride channel. Biol. Chem. (1999) 274:27415–27425.
  • MARIVINGT-MOUNIR C, NOREZ C, DERAND R et al.: Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. " Med. Chem. (2004) 47:962–972.
  • •Extensive SAR of benzoquinoliziniurns.
  • DERAND R, BULTEAU-PIGNOUX L, METTEY Y et al.: Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Jim. j Physiol (2001) 281:1657–1666.
  • DORMER R L, DERAND R, MCNEILLY C et al.: Correction of delF508-CFTR activity with benzoquinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. j. Cell Sci. (2001) 114:4073–4081.
  • •Evidence for correction by pharmacological chaperones of CF cells.
  • STRATFORD FL, PEREIRA MM, BECQ F, MCPHERSON MA, DORMER RL: Benz° (c)quinolizinium drugs inhibit degradation of AF508-CFTR cytoplamsic domain. Biochem. Biophys. Res. Commun. (2003) 300:524–530.
  • MCPHERSON MA, PEREIRA MM, LLOYD-MILLS C, MURRAY KJ, DORMER RL: A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein. FEBS Lett. (1999) 464:48–52.
  • ILLEK B, FISCHER H, SANTOS GE WIDDICOMBE JH, MACHEN TE, REENSTRA WW: cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am. Physiol (1995) 268:886–893.
  • ILLEK B, FISCHER H, MACHEN T: Alternate stimulation of apical CFTR by genistein in epithelia. Am. .1 Physiol (1996) 270:265–275.
  • DERAND R, BULTEAU-PIGNOUX L, BECQ F: The cystic fibrosis mutation G551D alters the non-Michaelis-Menten behavior of the cystic fibrosis transmembrane conductance regulator (CFTR) channel and abolishes the inhibitory genistein binding site." Biol. Chem. (2002) 277:35999–36004.
  • MELIN P, THOREAU V, NOREZ C, BILAN F, KITZIS A, BECQ F: The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein. Biochem. Pharmacol (2004) 67:2187–2196.
  • SPRINGSTEEL ME GALIETTA LI, MAT et al.: Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bio. Med. Chem. (2003) 11:4113–4120.
  • CACI E, FOLLI C, ZEGARRA-MORAN O et al.: CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am. .1 Physiol (2003) 285:180–188.
  • DUSZYK M, MAC VINISH L, CUTHBERT AW: Phenanthrolines - a new class of CFTR chloride channel openers. Br. Pharmacol (2001) 134:853–864.
  • CUTHBERT AW: Benzoquinolines and chloride secretion in murine colonic epithelium. Br. .1 Pharmacol (2003) 138:1528–1534.
  • CUTHBERT AW, MACVINISH LJ: Mechanisms of anion secretion in Calu-3 human airway epithelial cells by 7,8-benzoquinoline. Br. .1 Pharmacol (2003) 140:81–90.
  • SZKOTAK AJ, MURTHY M, McVINISH et al.: 4-chloro- benzo [Flisoquinoline (CBIQ) activates CFTR chloride channels and KCNN4 potassium channels in Calu-3 human airway epithelial cells. Br. .1 Pharmacol (2004) 142:531–542.
  • GALIETTA LIV, SPRINGSTEEL ME EDA M et al.: Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J. Biol. Chem. (2001) 276:19723–19728.
  • MAT, VETRIVEL L, YANG H et al.: High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. I Biol. Chem. (2002) 277:37235–37241.
  • •High-throughput screening discovery of CFTR modulators.
  • YANG H, SHELAT AA, GUY RK et al.: Nanomolar affinity small molecule correctors of defective AF508-CFTR chloride channel gating. I Biol. Chem. (2003) 278:35079–35085.
  • SAMMELSON RE, MAT, GALIETTA LIV, VERKMAN AS, KURTH MI: 3-(2-benzyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bio. Med. Chem. Lett. (2003) 13:2509–2512.
  • SINGH AK, DEVOR DC, GERLACH AC, GONDOR M, PILEWSKI JM, BRIDGES RI: Stimulation of Cl- secretion by chlorzoxazone." Pharm. Exp. Ther. (2000) 292:778–787.
  • DEVOR C, SINGH AK, BRIDGES RI, FRIZZELL RA: Psoralens: novel modulators of Cl- secretion. Am. .1 Physiol (1997) 272:976–988.
  • DEVOR DC, SINGH AK, BRIDGES RI, FRIZZELL RA: Modulation of Cr secretion by benzimidazolones. II. Coordinate regulation of apical GC1 and basolateral GK. Am. J. Physiol (1996) 271:785–795.
  • McCANN JD, WELSH MJ: Basolateral K+channels in airway epithelia. II. Role in Cl secretion and evidence for two types of K channels. Am. .1 Physiol. (1990) 258:343–348.
  • MALL M, WISSNER A, SCHREIBER R et at.: Role of KvLQT1 in cAMP-mediated Cl- secretion in human airway epithelia. Am. J. Respir. Cell Molec. Biol. (2000) 23:283–289.
  • BERNARD K, BOGLIOLO S, SORIANI O, EHRENFELD J: Modulation of calcium-dependent chloride secretion by basolateral SK4-like channels in a human bronchial cell line. J. Mem& Biol. (2003) 196:15–31.
  • MALL M, GONSKA T, THOMAS J et al.: Modulation of Ca2±-activated Cr secretion by basolateral K+ channels in human normal and cystic fibrosis airway epithelia. Pediatr. Res. (2003) 53:608–618.
  • SYME CA, GERLACH AC, SINGH AK, DEVOR DC: Pharmacological activation of cloned intermediate- and small-conductance Ca2±-activated K+ channels. Am. J. Physiol. (2000) 278:570–581.
  • JOINER WJ, WANG LY, TANG MD, KACZMAREK LK: hSK4, a member of a novel subfamily of calcium-activated potassium channels. Proc. Nati Acad. Sci. USA (1997) 94:11013–11018.
  • GRIBKOFF VK, CHAMPIGNY G, BABRY P, DWORETZKY SI, MEANWELL NA, LAZDUNSKI M: The substituted benzimidazolone N5004 is an opener of the cystic fibrosis chloride channel. ./. Biol. Chem. (1994) 269:10983–10986.
  • •First opener of CFTR.
  • AL-NAKKASH L, HU S, LI M, HWANG T-C: A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogues. Pharm. Exp. Ther. (2001) 296:464–472.
  • DEVOR DC, SINGH AK, FRIZZELL RA, BRIDGES RJ: Modulation of Cl secretion by benzimidazolones. I. Direct activation of a Ca2±-dependent K± channel. Am. .1. Physiol. (1996) 271:775–784.
  • DERAND R, BULTEAU-PIGNOUX L, BECQ F: Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative N5004. Membr. Biol. (2003) 194:109–117.
  • SINGH S, SYME CA, SINGH AK, DEVOR DC, BRIDGES RJ: Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. j. Pharm. Exp. Ther. (2001) 296:600–611.
  • OLESEN SP, MUNCH E, MOLDT P, DREJER J. Selective activation of Ca2±-dependent K+ channels by novel benzimidazolone. Ear: Pharmacol. (1994) 251:53–59.
  • GRAHAM A, HASANI A, ALTON EW et al.: No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur. Respir. (1993) 6:1243–1248.
  • PONS G, MARCHAND MC, D'ATHIS P et al.: French multicenter randomised double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr. Pulmonol. (2000) 30:25–31.
  • RODGERS HC, KNOX AJ: The effect oftopical benzamil and amiloride on nasal potential difference in cystic fibrosis. Ear: Respir. (1999) 14:693–696.
  • BRIDGES RJ, NEWTON BB, PILEWSKI JM, DEVOR DC, POLL CT, HALL RL: Na + transport in normal and CF human bronchial epithelial cells is inhibited by BAY 39-9437. Am. Physiol. (2001) 281:16–23.
  • HWANG TH, SCHWIEBERT EM, GUGGINO WB: Apical and basolateral ATP stimulate tracheal epithelial chloride secretion via multiple purinergic receptors and signalling pathways. Am. J. Physiol. (1996) 270:1611–1623.
  • CLARK LL, GRUBB BR, YANKASKAS JR, COTTON CU, McKENZIE A, BOUCHER RC: Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease in Cftr(-/-) mice. Proc. Natl. Acad. Sci. USA (1994) 91:479–483.
  • •Analysis of Ca2±-dependent CI secretion in mice lacking CFTR.
  • RUDOLF MT, DINKEL C, TRAYNOR-KAPLAN AE, SCHULTZ C: Antagonists of myo-Inositol 3,4,5, 6-tetrakisphophate allow repeated epithelial chloride secretion. Bioorg. Med. Chem. (2003) 11:3315–3329.
  • VAJANAPHANICH M, SCHULTZ C, RUDOLF MT et al.: Long-term uncoupling of chloride secretion from intracellular calcium levels by Ins(3,4,5,6)P4. Nature (1994) 371:711–714.
  • KACHINTORN U, VAJANAPHANICH M, BARRETT KE, TRAYNOR-KAPLAN AE: Elevation of inositol tetrakisphosphate parallels inhibition of Ca2+-dependent Cr secretion in T84 cells. Am Physiol. (1993) 264:671–676.
  • ZEITLIN PL, BOYLE MP, GUGGINO WB, MOLINA L: A Phase I trial of intranasal Moli1901 for cystic fibrosis. Chest (2004) 125:143–149.
  • CHANG XB, CUI L, HOU YX et al: Removal of multiple arginine-framed trafficking signals overcomes misprocessing of delta F508 CFTR present in most patients with cystic fibrosis. Mol. (1999) 4:137–142.
  • ••RXR sequences in the processing of CFTR.
  • OWSIANIK G, CAO L, NILIUS B: Rescue of functional D508-CFTR channels by co-expression with truncated CFTR constructs in COS-1 cells. FEBS Lett (2003) 554:173–178.
  • ZERANGUE N, SCHWAPPACH B, JAN YN, JAN LY: A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K(ATP) channels. Neuron (1999) 22:537–548.
  • XIE J, ADAM LM, ZHAO J, GERKEN TA, DAVIS PB, MA J: A short segment of the R domain of cystic fibrosis transmembrane conductance regulator contains channel stimulatory and inhibitory activities that are separable by sequence modification. I Biol. Chem (2002) 277:23019–23027.
  • VERKMAN AS: Drug discovery in academia. Am. .1 Physiol. (2004) 286:465–474.
  • ••An excellent review on HTS in anacademic laboratory.
  • ARIDOR M, HANNAN LA: Traffic jam: A compendium of human diseases that affect intracellular transport processes. Traffic (2000) 1:836–851.
  • ARID OR M, HANNAN LA: Traffic jam II: An update of diseases of intracellular transport. Traffic (2002) 3:781–790.

Websites

  • http://www.genet.sickkids.on.ca/cftr CF Gene consortium home page.
  • http://www.cfLorg Cystic Fibrosis foundation home page.
  • http://www.sciclone.com Sciclone Pharmaceuticals, Inc. home page.
  • http://www.inspirepharm.com Inspire Pharmaceuticals, Inc. home page.
  • http://inologic.com Inologic, Inc, Inc. home page.
  • http://www.molichemmedicines.com MoliChem Medicines, Inc. home page.
  • http://www.vrtx.com Vertex Pharmaceuticals, Inc. home page.
  • http://cfgenomics.unc.edu Home page of the Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.
  • http://www.genzyme.com Genzyme home page.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.